Samarth Kulkarni
Chief Executive Officer at CRISPR Therapeutics AG
Sits on 3 boards. Last updated September 27, 2026
Time on boards
- Boards served
- 3
- Current seats
- 3
- Board service
- 9 years
- Director since
- 2023
9 years of board service in total across 3 boards, counting each seat separately. Longest: CRISPR Therapeutics AG, 3 years.
Chief executive roles
Shareholder support
Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
CRISPR Therapeutics AG June 4, 202696.7%
-
Black Diamond Therapeutics Inc. June 12, 202541.2%
-
CRISPR Therapeutics AG June 5, 202598.1%
-
CRISPR Therapeutics AG May 30, 202498.8%
-
CRISPR Therapeutics AG June 8, 202397.6%
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Mar 23, 2026 | CRISPR Therapeutics AG | Open-market sale | −10,020 | $46.78 | $468,736 |
| Mar 20, 2026 | CRISPR Therapeutics AG | Option exercise | +19,687 | — | — |
| Mar 16, 2026 | CRISPR Therapeutics AG | Open-market sale | −10,349 | $48.26 | $499,443 |
| Mar 14, 2026 | CRISPR Therapeutics AG | Option exercise | +20,625 | — | — |
| Mar 11, 2026 | CRISPR Therapeutics AG | Open-market sale | −9,798 | $52.80 | $517,334 |
| Mar 10, 2026 | CRISPR Therapeutics AG | Option exercise | +19,250 | — | — |
| Feb 19, 2026 | CRISPR Therapeutics AG | Open-market sale | −6,967 | $52.58 | $366,325 |
| Feb 18, 2026 | CRISPR Therapeutics AG | Option exercise | +13,250 | — | — |
| Jan 22, 2026 | CRISPR Therapeutics AG | Open-market sale | −60,000 | $60.23 | $3,613,800 |
| Jan 20, 2026 | CRISPR Therapeutics AG | Open-market sale | −21,433 | $51.61 | $1,106,157 |
| Jan 20, 2026 | CRISPR Therapeutics AG | Open-market sale | −8,567 | $52.10 | $446,341 |
| Dec 18, 2025 | CRISPR Therapeutics AG | Gift | −30,000 | — | — |
| Oct 17, 2025 | CRISPR Therapeutics AG | Open-market sale | −50,895 | $67.91 | $3,456,279 |
| Oct 16, 2025 | CRISPR Therapeutics AG | Option exercise | +100,000 | — | — |
| Oct 14, 2025 | CRISPR Therapeutics AG | Open-market sale | −4,242 | $66.60 | $282,517 |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.